Earnings ·
Denali reports Q3 net income of $70.1M on $194M PRV sale gain; AVLAYAH revenue hits $17.8M
DNLIDenali Therapeutics Inc.
Denali Therapeutics reported a third-quarter net income of $70.1 million, driven by a one-time $194.0 million net gain from the sale of a Priority Review Voucher. The company generated $17.8 million in AVLAYAH net product revenue during its second full commercial quarter and raised Q4 2026 guidance to $30.0–$32.0 million. Cash, cash equivalents, and marketable securities totaled approximately $1.0 billion as of September 30, 2026. Denali Therapeutics is a biotechnology company pioneering blood-brain barrier therapeutics using its proprietary TransportVehicle platform.